COMMUNIQUÉS West-GlobeNewswire
-
GENFIT : Forte présence scientifique et stratégique au Congrès EASL 2026
25/05/2026 -
GENFIT Highlights Broad Scientific and Strategic Presence at EASL Congress 2026
25/05/2026 -
pH Wellness opens addiction treatment center in Lebanon, Tennessee
25/05/2026 -
Resolution Therapeutics congratulates University of Edinburgh on positive 4-year MATCH trial data on RMT in liver cirrhosis
25/05/2026 -
SeoProfy heads to Barcelona as a sponsor of Shoptalk Europe 2026
25/05/2026 -
Vireo Growth Inc. to Acquire Bridgewell Agribusiness LLC
25/05/2026 -
Grey Matters Improves Warrant Terms of Private Placement
25/05/2026 -
MEDIA ADVISORY -- Entire train cars of local residents head to Toronto for giant march to demand Doug Ford stop his unprecedented privatization of our public hospital services
25/05/2026 -
The hidden impact of veterinary care: new insights from a global survey of veterinarians
25/05/2026 -
Powerful Oral Steroids for Cutting Cycles 2026: Crazy Bulk Launches Effective Cutting Steroid Stacks for Strength and Muscle Growth
23/05/2026 -
Heallexa Launches AI Powered Healthcare Directory With Over 6 Million Provider Profiles to Make Finding and Booking Care More Convenient
23/05/2026 -
Dempster Therapeutic Services Launches “Chicago Speech Therapy” And “Polski logopeda” Digital Storefronts With Instant Online Booking, Patient Portal, And Rapid Access To Award-Winning Speech Therapy Services
23/05/2026 -
Roota Hair Growth Roll-On Scalp Serum & Roota Hair Activator Spray Under Investigation: Evaluating the Clinically-Tested Hair Care Formula's Claims
23/05/2026 -
Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026
22/05/2026 -
Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis
22/05/2026 -
XTL Announces Receipt of Staff Delist Determination from Nasdaq
22/05/2026 -
European Commission grants marketing authorization to Pharming’s Joenja® (leniolisib) – the first approved treatment for APDS in the European Union
22/05/2026 -
Abivax présente ses résultats financiers du T1 2026 et les données à trois ans de l’étude 108, un essai d’extension ouvert de phase 2a/2b évaluant l’obéfazimod après réduction de dose dans la RCH
22/05/2026 -
Leo International Precision Health AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
22/05/2026
Pages